Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
HRA Pharma - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'HRA Pharma - Product Pipeline Review - 2014', provides an overview of the HRA Pharma, SA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of HRA Pharma, SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of HRA Pharma including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of HRA Pharma's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the HRA Pharma's pipeline products Reasons to buy - Evaluate HRA Pharma's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of HRA Pharma in its therapy areas of focus - Identify new drug targets and therapeutic classes in the HRA Pharma's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of HRA Pharma and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of HRA Pharma - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of HRA Pharma and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 HRA Pharma Snapshot 4 HRA Pharma Overview 4 Key Information 4 Key Facts 4 HRA Pharma - Research and Development Overview 5 Key Therapeutic Areas 5 HRA Pharma - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 HRA Pharma - Pipeline Products Glance 9 HRA Pharma - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 HRA Pharma - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 HRA Pharma - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 HRA Pharma - Drug Profiles 13 HRA-081025 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 mifepristone 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ulipristal acetate 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 HRA-091015 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 HRA Pharma - Pipeline Analysis 18 HRA Pharma - Pipeline Products by Target 18 HRA Pharma - Pipeline Products by Route of Administration 19 HRA Pharma - Pipeline Products by Molecule Type 20 HRA Pharma - Pipeline Products by Mechanism of Action 21 HRA Pharma - Recent Pipeline Updates 22 HRA Pharma - Dormant Projects 25 HRA Pharma - Locations And Subsidiaries 26 Head Office 26 Other Locations & Subsidiaries 26 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables HRA Pharma, Key Information 4 HRA Pharma, Key Facts 4 HRA Pharma - Pipeline by Indication, , 2014 6 HRA Pharma - Pipeline by Stage of Development, 2014 7 HRA Pharma - Monotherapy Products in Pipeline, 2014 8 HRA Pharma - Phase III, 2014 9 HRA Pharma - Phase II, 2014 10 HRA Pharma - Phase I, 2014 11 HRA Pharma - Preclinical, 2014 12 HRA Pharma - Pipeline by Target, 2014 18 HRA Pharma - Pipeline by Route of Administration, 2014 19 HRA Pharma - Pipeline by Molecule Type, 2014 20 HRA Pharma - Pipeline Products by Mechanism of Action, 2014 21 HRA Pharma - Recent Pipeline Updates, 2014 22 HRA Pharma - Dormant Developmental Projects, 2014 25 HRA Pharma, Other Locations 26 HRA Pharma, Subsidiaries 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.